-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Orient (605116.SH) issued an announcement. Recently, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an estradiol didroprogesterone tablet “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is a hormone replacement therapy (HRT) medication and is suitable for treating symptoms of oestrogen deficiency in women at least 12 months after menopause.

Zhitongcaijing·11/19/2026 07:57:17
Listen to the news
Zhitong Finance App News, Orient (605116.SH) issued an announcement. Recently, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an estradiol didroprogesterone tablet “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is a hormone replacement therapy (HRT) medication and is suitable for treating symptoms of oestrogen deficiency in women at least 12 months after menopause.